Anticoagulation management of patients with recent heparin-induced thrombocytopenia (HIT) requiring cardiopulmonary bypass (CPB) surgery is a serious challenge, and especially difficult in patients requiring urgent heart transplantation. As non-heparin anticoagulants during CPB bear a high risk of major bleeding, these patients are at risk to be taken off the transplant list. Short-term use of unfractionated heparin (UFH) for CPB, with restriction of UFH to the surgery itself, is safe and effective in patients with a history of HIT who test negative for antiplatelet factor 4 (PF4)/heparin antibodies. We present evidence that it is safe to expand the concept of UFH-re-exposure to patients with subacute HIT, i.e. patients with recent HIT in whom the platelet count has recovered but in whom anti-PF4/heparin IgG antibodies remain detectable, requiring heart transplantation, if they test negative by a sensitive functional assay using washed platelets. This can be live-saving in patients with end-stage heart failure.
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Introduction:
Management of patients with recent heparin-induced thrombocytopenia (HIT) requiring cardiopulmonary bypass (CPB) surgery is a serious challenge for the consulting hematologist.
Particularly the choice of adequate anticoagulation management during CPB is problematic. The situation is especially difficult in patients requiring heart transplantation, as the timing of surgery usually cannot be planned in advance, whereas the use of alternative anticoagulants during CPB requires special monitoring and preparation 1,2 , and bears a significantly enhanced bleeding risk 3 .
A major conceptual breakthrough was the recognition that use of unfractionated heparin (UFH) for CPB in patients with a history of HIT is safe and effective, provided that circulating anti-PF4/heparin antibodies are no longer detectable 4 . This approach is now a Grade-1 recommendation for patients with a history of HIT requiring CPB 2 . However, optimal management of patients with subacute HIT in whom platelet counts have normalized, but in whom anti-PF4/heparin IgG antibodies are still detectable by enzyme-immunoassay (EIA), remains uncertain.
We report evidence that in these patients UFH is an option for anticoagulation during CPB if a sensitive functional assay using washed platelets, e.g. the heparin-induced platelet activation (HIPA) test 5 , is negative.
Material and Methods:
Anti-PF4/heparin antibodies were determined by EIA separately for IgG, IgA, and IgM 6 ;
heparin-dependent platelet-activating antibodies were determined by HIPA 5 . Heart transplantation was performed according to standard procedure using UFH adjusted by activated clotting time (ACT) and neutralized by protamine after CPB. Three days later a donor heart became available and heart transplantation was performed using standard UFH anticoagulation for CPB with no major bleeding (postoperative chest tube drainage 1200 mL in 48 hours). Lepirudin was restarted about 8 hours after surgery. Anti-PF4/heparin IgG antibodies increased at day 7 following transplantation (OD=1.248), but the Case III: A 44-year-old male patient was scheduled for heart transplantation for severe DCM and therapeutic-dose anticoagulation with phenprocoumon was switched to UFH (aPTT 50-60s). One week later, HIT developed (platelet count fall from 330x10 9 /L to 78x10 9 /L; positive anti-PF4/heparin EIA [HPIA, Diagnostica Stago, France], "4T's"-score=6). After switch to lepirudin (aPTT 50-60s), platelet counts normalized. Subsequent testing for HIT antibodies within 2 weeks showed a decrease of anti-PF4/heparin IgG levels (from OD 1.099 to 0.526; cutoff 0.500) and a negative HIPA. When a donor heart became available, lepirudin was stopped 4 hours before surgery. Anticoagulation during CPB was performed using standard UFH protocol, with no major bleeding (chest tube drainage 600 mL in the first postoperative 48 hours), lepirudin was restarted (aPTT 50-60s) 6 hours postoperatively ( Figure 1C ). The further course was complicated by prolonged cardiac shock and intensive care treatment. However, no thrombotic events occurred, and the patient was discharged 91 days after surgery.
Cessation of heparin and use of alternative non-heparin anticoagulation are basic therapeutic principles of HIT 2, 8 . Furthermore, heparin re-exposure in patients with circulating platelet-activating anti-PF4/heparin antibodies should be avoided, as this can cause "rapid-onset" HIT, complicated by thromboembolic events or anaphylactoid reactions 4, 9, 10 .
However, HIT antibodies unusually become undetectable within three months following an episode of HIT. Further, in patients with previous HIT in whom antibodies are no longer detectable, it takes at least five days for antibodies to recur following heparin re-exposure 4 .
These observations, together with the significantly enhanced bleeding risk if alternative anticoagulants are used during CPB 3 , has led to the strategy of short-term use of UFH for CPB surgery when the patient tests negative for HIT antibodies [11] [12] [13] , with restriction of heparin to the surgery itself. We now provide prospective data indicating that short-term use of UFH is feasible in patients with subacute HIT in whom anti-PF4/heparin IgG antibodies are still detectable by EIA, but who show a negative washed platelet activation assay. Washed platelet activating assays have a higher specificity for biologically active HIT antibodies and provide among all other HIT tests the best specificity for clinical HIT 16 . Therefore, a negative functional assay suggests that residual biologically-active antibodies are unlikely to be present 17, 18 . This strategy is feasible in countries in which functional HIT tests are available by a network of trained laboratories, providing the assays in a turnaround time and quality allowing to base clinical decisions on the test result (potential alternative approaches are given in Table 1 ).
In two of the patients no functional assay was performed at the time when acute HIT was diagnosed. However, the residually detectable anti-PF4/heparin IgG antibodies, together with the clinical presentation (Figure 1 ), were very suggestive of recent HIT when anticoagulant management during heart transplantation had to be decided. None of the three patients developed platelet-activating antibodies, and there was no evidence for HIT-related thrombotic events after re-exposure to UFH. As compared to non-HIT patients (illustrated as grey shaded area in the figure), however, platelet count recovery after heart transplantation seemed to be somewhat delayed. This might indicate that the persistent antibodies, although not causing thrombosis, may still impair platelet count recovery. days of heparin treatment, the positive anti-PF4/heparin IgG, the positive HIPA, and the rapid increase of platelet count after switching from heparin to argatroban. Criteria to diagnose HIT in patient II were: the platelet fall >50% after 7 days of heparin treatment, complicated by iliac artery embolism, the positive anti-PF4/heparin IgGAM by a commercial EIA, and the rapid increase of platelet count after switching from heparin to lepirudin. Criteria to diagnose HIT in patient III were: the platelet fall >50% after 7 days of heparin treatment, the positive anti-PF4/heparin IgGAM by a commercial EIA, and the rapid increase of platelet count after switching from heparin to lepirudin. (CPB-cardiopulmonary bypass, IABP-intraaortic balloon pump, OD-optical density). 16 ) are not commercially available and require specialized laboratories. Access to functional assays varies between medical systems. In some countries a network of trained laboratories offers the HIPA test with a ≤ 48h turnaround time, while in other countries it is a major problem to get samples tested within reasonable time for clinical decision processes. In these settings, there is increasing evidence that some maneuvers may help to use the PF4/heparin enzyme immunoassay (EIA) alone for deciding on the strategy of anticoagulation during cardiac surgery or heart transplantation. These maneuvers are not optimal, but given the consequences of taking a patient off the heart transplant list they might be acceptable. 14 . Grade of recommendation 2C †2 . In this case it is a feasible backup safety measure to have epoprostenol or tirofiban at hand during surgery which could be given in case clotting starts to manifest during surgery due to HIT antibodies. Both substances will to immediately block platelet activation or aggregation, respectively. Grade of recommendation 2C †2 .
